In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company's stock price to fall by as much as 29%. Yes, fall. For anyone not following the heated race for obesity drug dominance, it may look like we're living upside-down. After all, if this data were unveiled three years ago, the market reaction would have been wildly different. The stock might have gone up and headlines would have heralded an advance in the fight against obesity. But we're in a new era of obesity medicine. The bar for success, once modest, has soared—especially so for CagriSema. Let me explain.
Though Novo will make mind-blowing money from its existing obesity drugs in the coming years (its GLP-1 drugs are likely to become pharma's most lucrative franchise next year), CagriSema was seen as essential for continued growth in 2030 and beyond. And the study suggests it may not be the contender investors had hoped for.
This story is from the January 02, 2025 edition of Mint Hyderabad.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the January 02, 2025 edition of Mint Hyderabad.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Address India's worsening urban groundwater crisis
We require innovative solutions that use technology to prevent its depletion and contamination
NSE's investor registrations breach 110 mn mark
In the last five months, daily new registrations have ranged 47,000 to 73,000, adding a massive 10 million investors
US sanctions won't see oil price surge, shipping to be hit
Oil price is not projected to rise, may stay at $70-75 a barrel, and the situation will ease in a few months: BPCL CMD
India Uses AI to Stop Stampedes at World's Biggest Gathering
Keen to improve India's abysmal crowd management record at large-scale religious events, organisers of the world's largest human gathering are using artificial intelligence to try to prevent stampedes.
A Liveable Planet Must Remain on the Agenda
People of over 340 districts are highly vulnerable to the health effects of climate change
Strategies to achieve ₹1 cr with a current portfolio of ₹47.4 lakh
I'm 28 years with a ₹47.4 lakh portfolio (₹36.5 lakh in equities, rest in mutual funds). I invest ₹25,000 via monthly SIPs, increasing 10% annually. With no liabilities, I plan to invest ₹10 lakh more. How can I grow my portfolio to ₹1 crore in two years, or by 30 years?
HDFC Bank NPAs rise amid Q3 agriculture loan defaults
The lender's profit growth was weighed down by asset quality issues and slow loan growth
Netflix surges past 300 mn subscribers
Netflix on Tuesday said it added nearly 19 million subscribers during the holiday season to finish out last year with more than 300 million subscribers.
Travel unicorn OYO eyes religious hubs
Travel tech unicorn OYO on Wednesday said it is planning to add 500 hotels in religious hubs, including Ayodhya, Varanasi, Prayagraj, Puri, Haridwar, Mathura, Vrindavan, Amritsar, Ujjain, Ajmer, Nasik and Tirupati, this year.
Blue Energy Motors to invest ₹3,500 cr
NG-powered truck maker Blue Energy Motors on Wednesday said it plans to invest ₹3,500 crore for setting up an electric trucks production plant in Maharashtra to fuel the state's green energy transition.
